-
Product Insights
Primary Sclerosing Cholangitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Drugs In Development, 2023’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cholangitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cholangitis - Drugs In Development, 2023’, provides an overview of the Cholangitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Uveal Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveal Melanoma - Drugs In Development, 2023’, provides an overview of the Uveal Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...